- Home
- FLO vs AUPH Comparison
FLO vs AUPH Comparison
Compare FLO & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLO | AUPH |
|---|---|---|
| Founded | 1919 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FLO | AUPH |
|---|---|---|
| Price | $8.79 | $15.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $11.20 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 4.4M | 1.1M |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.63% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | 0.40 | ★ 2.07 |
| Revenue | ★ $5,256,479,000.00 | $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | $0.65 | $15.74 |
| P/E Ratio | $21.24 | ★ $7.76 |
| Revenue Growth | 3.00 | ★ 20.38 |
| 52 Week Low | $7.86 | $7.29 |
| 52 Week High | $18.53 | $16.54 |
Technical Indicators
Market Signals| Indicator | FLO | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 60.86 |
| Support Level | $7.86 | $14.56 |
| Resistance Level | $9.03 | $16.28 |
| Average True Range (ATR) | 0.30 | 0.47 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 97.91 | 75.84 |
Price Performance
Historical ComparisonAbout FLO Flowers Foods Inc.
Flowers Foods Inc operates as a producer and marketer of packaged bakery foods in the United States. Its principal products include breads, buns, rolls, snack items (bars, cakes, cookies, and crackers), bagels, English muffins, tortillas, and baking mixes. These products are sold under the brand names Nature's Own, Dave's Killer Bread (DKB), Canyon Bakehouse, Simple Mills, Wonder, and Tastykake. The company derives the majority of its revenue from the sales of its bakery products.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.